Walter Public Investments Inc. Increases Stock Position in Novo Nordisk A/S (NYSE:NVO)

Walter Public Investments Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 5.5% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 209,977 shares of the company’s stock after purchasing an additional 10,920 shares during the period. Novo Nordisk A/S comprises 2.7% of Walter Public Investments Inc.’s holdings, making the stock its 18th biggest position. Walter Public Investments Inc.’s holdings in Novo Nordisk A/S were worth $14,581,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. Bank Hapoalim BM raised its stake in shares of Novo Nordisk A/S by 161.7% during the 1st quarter. Bank Hapoalim BM now owns 22,535 shares of the company’s stock worth $1,565,000 after acquiring an additional 13,925 shares in the last quarter. Beverly Hills Private Wealth LLC raised its stake in shares of Novo Nordisk A/S by 19.5% during the 1st quarter. Beverly Hills Private Wealth LLC now owns 43,203 shares of the company’s stock worth $3,000,000 after acquiring an additional 7,048 shares in the last quarter. Crossmark Global Holdings Inc. raised its stake in shares of Novo Nordisk A/S by 1.6% during the 1st quarter. Crossmark Global Holdings Inc. now owns 51,937 shares of the company’s stock worth $3,607,000 after acquiring an additional 841 shares in the last quarter. Fullcircle Wealth LLC raised its stake in shares of Novo Nordisk A/S by 31.9% during the 1st quarter. Fullcircle Wealth LLC now owns 26,038 shares of the company’s stock worth $1,808,000 after acquiring an additional 6,292 shares in the last quarter. Finally, U.S. Capital Wealth Advisors LLC raised its stake in shares of Novo Nordisk A/S by 26.6% during the 1st quarter. U.S. Capital Wealth Advisors LLC now owns 8,773 shares of the company’s stock worth $609,000 after acquiring an additional 1,843 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Hsbc Global Res upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, April 28th. BNP Paribas assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating on the stock. Wall Street Zen upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Saturday, June 14th. Finally, Guggenheim lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $112.00.

Novo Nordisk A/S Stock Up 0.2%

NYSE:NVO opened at $69.31 on Tuesday. The firm has a market capitalization of $309.47 billion, a P/E ratio of 20.51, a PEG ratio of 1.35 and a beta of 0.64. Novo Nordisk A/S has a 1-year low of $57.00 and a 1-year high of $143.69. The company’s fifty day moving average price is $70.10 and its 200-day moving average price is $75.41. The company has a debt-to-equity ratio of 0.70, a current ratio of 0.74 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The firm had revenue of $11.87 billion for the quarter. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.